Introduction Seminar About Patient Participation and Treatment Options for Psychiatric Patients on Waiting List

Introduction Seminar About Patient Participation and Treatment Options for Patients on Waiting List in a Community Mental Health Centre - Development, Effect, Experiences and Costs

Patient participation is a central concept in Norwegian health policy. It is mandatory in hospitals and emphasised as one of the most prioritised areas by the Government. Studies from Norway have repeatedly found that patients who seek help in community mental health centres ("DPS") are dissatisfied with the information they receive and about their possibility for real influence in their treatment.

One way to improve individual patient participation might be to give patients information before they start their treatment. This can be done as group based patient education to reduce the resources needed. Furthermore, as there are waiting lists for treatment, such introduction seminars could be held while patients are waiting to use this time in a meaningful way.

The present study therefore aims at testing the effect of an introduction seminar for patients on waiting list in a community mental health centre.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

92

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Trondheim, Norway, 7055
        • Tiller DPS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients older than 18 years referred for out patient treatment who get a guarantee of starting treatment between 2 and 6 months will be included.

Exclusion Criteria:

  • patients with a guarantee of starting treatment in less than two months and
  • patients who do not understand the consequences of taking part in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Usual care
Usual care
Experimental: Introduction seminar
Psychoeducation for patients on waiting list
The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.
Other Names:
  • psychoeducation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Behavior and symptoms
Time Frame: 12 months
Behavior and Symptom Identification Scale (BASIS-32)
12 months
knowledge on treatment preference
Time Frame: 1 month
1 month
patient activation (coping)
Time Frame: 4 months
measured with Patient Activation Measure (PAM)
4 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Client satisfaction
Time Frame: Baseline, 4 and 12 months
Satisfaction measured with Client Satisfaction Questionnaire (CSQ-8)
Baseline, 4 and 12 months
Perceived participation
Time Frame: Baseline, 4 and 12 months
Perceived participation measured with Perception of care (PoC)
Baseline, 4 and 12 months
Psychiatric Out-Patient Experiences
Time Frame: Baseline, 4 and 12 months
Psychiatric Out-Patient Experiences Questionnaire (POPEQ)
Baseline, 4 and 12 months
Quality of Life
Time Frame: Baseline, 4 and 12 months
WHO-5
Baseline, 4 and 12 months
motivation for treatment
Time Frame: Baseline, 1 and 4 months
motivation for treatment (questions)
Baseline, 1 and 4 months
costs
Time Frame: Baseline, 1, 4 and 12 months
data on health care use, sick leave, medication and other direct and indirect costs will be collected
Baseline, 1, 4 and 12 months
Knowledge
Time Frame: Baseline, 1, 4 and 12 months
measured using a self developed questionnaire
Baseline, 1, 4 and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2009

Primary Completion (Actual)

June 1, 2011

Study Completion (Actual)

July 1, 2012

Study Registration Dates

First Submitted

August 26, 2009

First Submitted That Met QC Criteria

August 26, 2009

First Posted (Estimate)

August 27, 2009

Study Record Updates

Last Update Posted (Actual)

September 5, 2018

Last Update Submitted That Met QC Criteria

August 31, 2018

Last Verified

August 1, 2018

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mental Disorders

Clinical Trials on Usual care

3
Subscribe